
Cumberland Pharmaceuticals CPIX
$ 4.78
-7.96%
Quarterly report 2025-Q3
added 11-07-2025
Cumberland Pharmaceuticals Total Shareholders Equity 2011-2026 | CPIX
Annual Total Shareholders Equity Cumberland Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.9 M | 29.6 M | 36.3 M | 42.8 M | 47 M | 51.1 M | 55.8 M | 64.1 M | 73.2 M | 76.9 M | 80.8 M | 79.5 M | 85.7 M | 82.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 85.7 M | 22.9 M | 59.2 M |
Quarterly Total Shareholders Equity Cumberland Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.1 M | 28 M | 28.7 M | 22.9 M | 24.5 M | 26 M | 27.2 M | 29.6 M | 35.7 M | 36.8 M | 36 M | 36.3 M | 38.9 M | 39.2 M | 40.8 M | 42.8 M | 46.6 M | 47.8 M | 46.9 M | 47 M | 47 M | 47 M | 47 M | 51.1 M | 51.7 M | 51.1 M | 55.4 M | 55.8 M | 55.8 M | 55.8 M | 55.8 M | 64.1 M | 64.1 M | 64.1 M | 64.1 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 76.9 M | 76.9 M | 76.9 M | 76.9 M | 80.8 M | 80.8 M | 80.8 M | 80.8 M | 79.5 M | 79.5 M | 79.5 M | 79.5 M | 85.7 M | 85.7 M | 85.7 M | 85.7 M | 82.9 M | 82.9 M | 82.9 M | 82.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 85.7 M | 22.9 M | 58.5 M |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
487 M | $ 1.28 | 7.8 % | $ 138 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
649 M | $ 13.4 | -3.67 % | $ 686 M | ||
|
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | ||
|
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.48 | -0.09 % | $ 2.04 B | ||
|
Sundial Growers
SNDL
|
270 M | $ 1.65 | -0.3 % | $ 3.37 M | ||
|
Evolus
EOLS
|
5.52 M | $ 5.72 | 0.97 % | $ 355 M | ||
|
Harrow Health
HROW
|
70.8 M | $ 50.59 | -0.81 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
7.75 M | $ 1.39 | 2.21 % | $ 24.3 M | ||
|
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
300 M | $ 1.74 | 3.57 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
-1.02 B | $ 7.81 | -1.2 % | $ 2.85 B | ||
|
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
2.13 B | $ 4.25 | 0.12 % | $ 86.3 M | ||
|
Organogenesis Holdings
ORGO
|
263 M | $ 4.25 | -1.28 % | $ 560 M | ||
|
Pacira BioSciences
PCRX
|
778 M | $ 26.09 | 0.35 % | $ 1.21 B | ||
|
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
4.32 B | $ 14.84 | 1.64 % | $ 2.04 B | ||
|
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | ||
|
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
21.3 M | $ 1.0 | 4.65 % | $ 23.3 M | ||
|
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.4 | 1.85 % | $ 132 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.82 | 1.33 % | $ 4.74 M | ||
|
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
138 M | $ 9.4 | -0.32 % | $ 668 M | ||
|
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
137 M | $ 5.32 | -5.17 % | $ 217 M | ||
|
Tilray
TLRY
|
3.32 B | $ 9.13 | 1.57 % | $ 5.64 B | ||
|
SCYNEXIS
SCYX
|
73 M | $ 0.67 | 3.96 % | $ 32.1 M | ||
|
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | ||
|
Veru
VERU
|
32.3 M | $ 2.32 | -2.11 % | $ 313 M | ||
|
TherapeuticsMD
TXMD
|
29.3 M | $ 2.01 | -1.62 % | $ 21 M | ||
|
cbdMD
YCBD
|
1.96 M | $ 1.1 | - | $ 4.74 M | ||
|
Viatris
VTRS
|
21.1 B | $ 12.61 | 1.16 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
240 M | - | -0.21 % | $ 98 M |